REG1 [anivamersen-pegnivacogin] multiple dosing in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2008
At a glance
- Drugs Anivamersen-pegnivacogin (Primary)
- Indications Acute coronary syndromes; Venous thrombosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Regado Biosciences
- 03 Sep 2008 Results have been published in the proceedings of the ESC Congress 2008: Annual Congress of the European Society of Cardiology.
- 09 Nov 2007 New trial record.